公开(公告)号：US20160222117A1

公开(公告)日：2016-08-04

申请号：US14846457

申请日：2015-09-04

Applicant: GENENTECH, INC.

Inventor： Bryan IRVING ,  Henry CHIU ,  Heather MAECKER ,  Sanjeev MARIATHASAN ,  Sophie M. LEHAR ,  Yan WU ,  Jeanne CHEUNG

IPC: C07K16/28 ,  C07K16/30

CPC classification number: C07K16/2827 ,  A61K31/7068 ,  A61K39/00 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/1063 ,  C07K16/22 ,  C07K16/28 ,  C07K16/30 ,  C07K16/3046 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/423 ,  Y02A50/489 ,  Y02A50/492 ,  A61K2300/00

Abstract: The present application relates to nucleic acid encoding anti-PD-L1 antibodies, which have therapeutic use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

Abstract translation: 本申请涉及编码抗PD-L1抗体的核酸，其具有治疗用途，其具有增强T细胞功能以上调细胞介导的免疫应答和用于治疗T细胞功能障碍性疾病，包括感染（例如急性和慢性 ）和肿瘤免疫。

公开(公告)号：US20140235828A1

公开(公告)日：2014-08-21

申请号：US14103715

申请日：2013-12-11

Applicant: AIMM THERAPEUTICS B.V. ,  Genentech, Inc

Inventor： Tim BEAUMONT ,  Mark Jeroen KWAKKENBOS ,  Eric J. BROWN ,  John Hiroshi MORISAKI ,  Wouter L.W. HAZENBOS ,  Sanjeev MARIATHASAN ,  Kimberly KAJIHARA ,  Yi XIA

IPC: C07K16/12

CPC classification number: G01N33/5091 ,  C07K16/1271 ,  C07K16/1278 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2469/10 ,  G01N2800/26

Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

Abstract translation: 本发明提供能够特异性结合革兰氏阳性细菌的改进的结合化合物。 提供了完全人类的结合化合物，可在人类个体中实现治疗应用。

公开(公告)号：US20130261293A1

公开(公告)日：2013-10-03

申请号：US13786215

申请日：2013-03-05

Applicant: GENENTECH, INC.

Inventor： Tim BEAUMONT ,  Mark Jeroen KWAKKENBOS ,  Eric J. BROWN ,  John Hiroshi MORISAKI ,  Wouter L.W. HAZENBOS ,  Sanjeev MARIATHASAN ,  Kimberly KAJIHARA ,  Yi XIA

IPC: C07K16/12

CPC classification number: G01N33/5091 ,  C07K16/1271 ,  C07K16/1278 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2469/10 ,  G01N2800/26

Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

公开(公告)号：US20240190967A1

公开(公告)日：2024-06-13

申请号：US18237114

申请日：2023-08-23

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Marcin KOWANETZ ,  Gregg FINE ,  Sanjeev MARIATHASAN ,  Richard BOURGON

IPC: C07K16/28 ,  A61K39/00 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: C07K16/2827 ,  C12Q1/6886 ,  G01N33/57407 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N2333/70532 ,  G01N2800/52

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

公开(公告)号：US20230151103A1

公开(公告)日：2023-05-18

申请号：US17886809

申请日：2022-08-12

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Luciana MOLINERO ,  Sanjeev MARIATHASAN ,  Shannon TURLEY ,  Jillian ASTARITA ,  Rafael CUBAS ,  Yagai YANG

IPC: C07K16/28 ,  C12Q1/6886 ,  A61P35/00 ,  G01N33/574

CPC classification number: C07K16/2866 ,  A61P35/00 ,  C07K16/2827 ,  C12Q1/6886 ,  G01N33/5743 ,  G01N33/57415 ,  G01N33/57492 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/75 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The invention provides methods for identifying an individuals with a disease or disorder who is less likely to respond to immunotherapy alone, the method comprising determining the presence of a stromal gene signature in a sample from the individual, said signature comprising one or more of FAP, FN1, MMP2, PDGFRB, or THY, wherein an increase in the level of expression of the one or more genes in the stroma gene signature relative to a median level identifies an individual for treatment with an immunotherapy and with a suppressive stromal antagonist. In some aspects, the invention provides methods for treating an individual displaying the stromal gene signature. In other aspects, the invention provides kits for determining the presence of a stroma gene signature in a sample from an individual.

公开(公告)号：US20190016807A1

公开(公告)日：2019-01-17

申请号：US15881611

申请日：2018-01-26

Applicant: Genentech, Inc.

Inventor： Bryan IRVING ,  Henry CHIU ,  Heather MAECKER ,  Sanjeev MARIATHASAN ,  Sophie M. LEHAR ,  Yan WU ,  Jeanne CHEUNG

IPC: C07K16/28 ,  C07K16/10 ,  C07K16/22 ,  A61K31/7068 ,  C07K16/30 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

公开(公告)号：US20170107287A1

公开(公告)日：2017-04-20

申请号：US15335278

申请日：2016-10-26

Applicant: Genentech, Inc.

Inventor： Bryan IRVING ,  Henry CHIU ,  Heather MAECKER ,  Sanjeev MARIATHASAN ,  Sophie M. LEHAR ,  Yan WU ,  Jeanne CHEUNG

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2827 ,  A61K31/7068 ,  A61K39/00 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/1063 ,  C07K16/22 ,  C07K16/28 ,  C07K16/30 ,  C07K16/3046 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/423 ,  Y02A50/492 ,  A61K2300/00

Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

公开(公告)号：US20170067880A1

公开(公告)日：2017-03-09

申请号：US15246301

申请日：2016-08-24

Applicant: Genentech, Inc. ,  AIMM Therapeutics B.V.

Inventor： Tim BEAUMONT ,  Mark Jeroen KWAKKENBOS ,  Eric J. BROWN ,  John Hiroshi MORISAKI ,  Wouter L.W. HAZENBOS ,  Sanjeev MARIATHASAN ,  Kimberly KAJIHARA ,  Yi XIA

IPC: G01N33/50 ,  C07K16/12 ,  G01N33/68

CPC classification number: G01N33/5091 ,  C07K16/1271 ,  C07K16/1278 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2469/10 ,  G01N2800/26

Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

Abstract translation: 本发明提供能够特异性结合革兰氏阳性细菌的改进的结合化合物。 提供了完全人类的结合化合物，可在人类个体中实现治疗应用。

公开(公告)号：US20220153861A1

公开(公告)日：2022-05-19

申请号：US17590918

申请日：2022-02-02

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： Richard BOURGON ,  David FABRIZIO ,  Gregg FINE ,  Garrett M. FRAMPTON ,  Priti HEGDE ,  Sanjeev MARIATHASAN ,  Philip J. STEPHENS ,  James Xin SUN ,  Roman YELENSKY

IPC: C07K16/28 ,  A61K39/395 ,  G16H50/30

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).

公开(公告)号：US20210208143A1

公开(公告)日：2021-07-08

申请号：US17205640

申请日：2021-03-18

Applicant: Genentech, Inc.

Inventor： Sanjeev MARIATHASAN

IPC: G01N33/574 ,  A61P35/04 ,  C07K16/28 ,  A61K9/00 ,  A61K45/06 ,  A61K39/395

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for bladder cancer (e.g., a locally advanced or metastatic urothelial carcinoma). The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient).